EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Glucagon-like peptide-1 receptor agonist use in pregnancy: a review

Rosa F Drummond, Karl E Seif, E Albert Reece

American Journal of Obstetrics and Gynecology · 2025-01 · 232 (1) · 17-25

DOI: 10.1016/j.ajog.2024.08.024 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Obstetrics and Gynecology, 2025-01. Verfasst von Rosa F Drummond und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Maternal Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Maryland School of Medicine and M…. Hauptthemen laut MEDLINE: Abnormalities, Drug-Induced, Diabetes Mellitus, Type 2, Obesity, Pregnancy in Diabetics. Die Arbeit wurde bisher 100-mal zitiert (Crossref) und nennt 60 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide-1 receptor agonists are peptide analogues that are used to treat type 2 diabetes mellitus and obesity. The first medication in this class, exenatide, was approved in 2005, and these medications, specifically semaglutide, have become more popular in recent years due to their pronounced effects on glycemic control, weight reduction, and cardiovascular health. Due to successful weight loss from these medications, many women previously diagnosed with oligomenorrhea and unable to conceive have experienced unplanned pregnancies while taking the medications. However, there are currently little data for clinicians to use in counseling patients in cases of accidental periconceptional exposure. In some studies examining small animals exposed to glucagon-like peptide-1 receptor agonists in pregnancy, there has been evidence of adverse outcomes in the offspring, including decreased fetal growth, skeletal and visceral anomalies, and embryonic death. Although there are no prospective studies in humans, case reports, cohort studies, and population-based studies have not shown a pattern of congenital anomalies in infants. A recent large, observational, population-based cohort study examined 938 pregnancies affected by type 2 diabetes mellitus and compared outcomes from periconceptional exposure to glucagon-like peptide-1 receptor agonists and insulin. The authors concluded there was not a significantly increased risk of major congenital malformations in patients taking glucagon-like peptide-1 receptor agonists, although there was no information on maternal glycemic control or diabetic fetopathy. As diabetic embryopathy is directly related to the degree of maternal hyperglycemia and not the diagnosis of diabetes itself, it is not possible to make this conclusion without this information. Furthermore, there is little evidence available regarding fetal growth restriction, embryonic or fetal death, or other potential complications. At this time, patients should be counseled there is not enough evidence to predict any adverse effects, or the lack thereof, of periconceptional exposure of glucagon-like peptide-1 receptor agonists during pregnancy. We recommend that all patients use contraception to prevent unintended pregnancy while taking glucagon-like peptide-1 receptor agonists.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Abnormalities, Drug-InducedDiabetes Mellitus, Type 2ObesityPregnancy in DiabeticsGlucagon-Like Peptide-1 Receptor AgonistsAnimalsFemaleHumansPregnancyExenatidePregnancy OutcomeSemaglutide

Stichwörter der Autor:innen

PCOSabortiondiabetic fetopathydulaglutideembryonic deathexenatidefetal anomaliesfetal deathfetal growth restrictionglucagon-like peptide-1 receptor agonistsglycemic controlhyperglycemiainsulin resistanceliraglutidelixisenatide

Substanzen

ExenatideGlucagon-Like Peptide-1 Receptor AgonistsSemaglutide

Autor:innen und Institutionen

  • Division of Maternal Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Maryland School of Medicine and Medical Center, Baltimore, MD. Electronic address: rosa.drummond@umm.ed…
  • Division of Maternal Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Maryland School of Medicine and Medical Center, Baltimore, MD.

Zitieren

APA

Drummond, R. F., Seif, K. E., & Reece, E. A. (2025). Glucagon-like peptide-1 receptor agonist use in pregnancy: a review. American Journal of Obstetrics and Gynecology, 232(1), 17-25. https://doi.org/10.1016/j.ajog.2024.08.024

Vancouver

Drummond RF, Seif KE, Reece EA. Glucagon-like peptide-1 receptor agonist use in pregnancy: a review. American Journal of Obstetrics and Gynecology. 2025;232(1):17-25. doi:10.1016/j.ajog.2024.08.024

BibTeX
@article{Drummond2025,
  author = {Drummond, Rosa F and Seif, Karl E and Reece, E Albert},
  title = {Glucagon-like peptide-1 receptor agonist use in pregnancy: a review},
  journal = {American Journal of Obstetrics and Gynecology},
  year = {2025},
  volume = {232},
  number = {1},
  pages = {17--25},
  doi = {10.1016/j.ajog.2024.08.024}
}
Kostenlos starten →